Daily Newsletter

22 November 2023

Daily Newsletter

22 November 2023

Quest and Talkiatry expand access to virtual psychiatric care

Quest will address mental health crisis in the workplace by offering in-network, virtual psychiatric care through Talkiatry.

November 21 2023

Quest Behavioral Health has partnered with Talkiatry to offer virtual psychiatric care services to its 125,000 members and their families.

A mental health and substance use disorder benefits administrator, Quest Behavioral Health aims to address the mental health crisis in the workplace by offering in-network, virtual psychiatric care through Talkiatry.

The collaboration allows members to connect with Talkiatry's virtual psychiatric care services, reducing wait times and ensuring continuity of care.

This initiative is said to be crucial in Pennsylvania, where approximately two million people experience mental illness, while hurdles such as a lack of in-network options hinder access to treatment.

Talkiatry's services are covered by over 60 plans, with the bulk of the visits costing patients about $30 or below after insurance.

The partnership seeks to alleviate the financial burden on patients and contribute to improved mental health outcomes for employees and their families within Quest Behavioral Health's network.

Currently, Talkiatry is hiring psychiatrists and psychotherapists in Pennsylvania to meet the growing demand for virtual psychiatric care services.

Talkiatry CEO and co-founder Robert Krayn said: “The mental health crisis sweeping the US is only made worse when people don't have easy access to providers and have to navigate complex insurance issues that discourage them from seeking care.

“It's through partnerships with innovators like Quest Behavioral Health that we can start to address those challenges and streamline access to quality, affordable care so that more people can receive mental health and psychiatric support when they need it.”

Is it time for the healthcare sector to fully embrace the benefits of digitalization and AI?

Only a handful of approved therapeutic drugs are currently available for the treatment of ARF, all belonging to the solute carrier family 12 member 1 inhibitor. The clinical trial space in ARF consists of almost an equal mix of commercial as well as academic sponsors, with Iran and the US emerging as the key countries for conducting Phase III trials. While the current marketed drug space for ARF has only a handful of treatment options, currently available mid-to-late-stage pipeline drugs are likely to pave the way for a new treatment approach in the future.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close